Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-derived Mesenchymal Stem Cell Gel for Knee Cartilage Damage
NCT03955497Phase 2Unknown
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in knee osteoarthritis (OA) and osteoarthritis (OA) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Hospital for Special Surgery Knee Score at 36 months, Visual Analogue Scale at 36 months and 4 more. Status: unknown.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03955497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955497.